论文部分内容阅读
目的研究rh-Endostatin靶向疗法在恶性肿瘤患者中的临床治疗效果及对细胞免疫的影响,为临床提供依据。方法选取2014-05-2016-04医院诊治的恶性肿瘤患者60例,根据治疗措施不同将患者分为对照组30例和观察组30例,对照组采用姑息减症治疗,观察组采用rh-Endostatin靶向疗法治疗,患者治疗前后采集静脉血,利用流式细胞仪测定细胞免疫指标,比较两组临床疗效及对细胞免疫的影响。结果观察组患者治疗2个周期疗效率、获益率显著高于对照组,P<0.05;两组患者治疗前细胞免疫细胞如CD3~+、CD4~+及CD8~+差异无统计学意义,P>0.05;观察组治疗后CD3~+、CD4~+显著高于对照组,P<0.05;观察组治疗后CD8~+显著低于对照组,P<0.05。结论与姑息减症治疗相比,恶性肿瘤患者采用rh-Endostatin靶向疗法治疗效果理想,能提高细胞免疫功能,值得推广应用。
Objective To study the clinical efficacy of rh-Endostatin targeted therapy in patients with malignant tumors and its effect on cellular immunity, and provide a basis for clinical practice. Methods Sixty patients with malignant tumors diagnosed and treated in our hospital from May 2014 to May 2016 were selected. The patients were divided into control group (30 cases) and observation group (30 cases) according to the different treatment measures. The control group was treated with palliative treatment. The observation group was given rh-Endostatin Targeted therapy, venous blood was collected before and after treatment, the cellular immune parameters were measured by flow cytometry, and the clinical curative effect and the effect on cellular immunity were compared between the two groups. Results The therapeutic efficiency of the two groups in the observation group was significantly higher than that in the control group (P <0.05). There was no significant difference in the number of cellular immune cells such as CD3 +, CD4 + and CD8 + before treatment in the two groups, P> 0.05; CD3 ~ +, CD4 ~ + in the observation group after treatment was significantly higher than that in the control group, P <0.05; CD8 ~ + in the observation group was significantly lower than that in the control group, P <0.05. Conclusion Compared with the treatment of palliative disease, the treatment of malignant tumor patients with rh-Endostatin target therapy is effective and can improve cellular immune function, which is worth popularizing and applying.